IQVIA Holdings Inc. (IQV)
NYSE: IQVHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 7, 4:03 PM ET · Delayed 15 min
IQV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $42.48B
- P/E (TTM)
- 32.30
- Forward P/E
- 17.87
- EPS (TTM)
- $7.99
- Dividend yield
- None
- 52-week range
- 154.50 – 277.40
- Day range
- 255.05 – 261.41
- Volume / Avg
- 1.41M / 1.44M
- Beta
- —
- Shares outstanding
- 164.60M
- Next earnings
- Oct 27, 2026
52-week range
IQV stock today
On Oct 7, IQV ended the session at $258.11, shedding $1.87 (0.72%), versus the S&P 500's 0.22% decline. At this level, IQV sits near the top of its 52-week range of $154.50 to $277.40: 7.0% below the high, set on Sep 23, 2026 and 67.1% above the low. IQV is up 14.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 28.7%.
At 32.3x trailing earnings, IQVIA trades in line with the peer-group median of 35.5x. Its forward P/E of 17.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 27 before the market opens; analysts expect EPS of $2.95.
Summary generated from market data by MetaCap's automated system. Methodology
About IQVIA
Company profileIQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. Ari Bousbib
- Headquarters
- Durham, NC
- Employees
- 94,000
- IPO year
- 2013
- Website
- iqvia.com
Financial highlights
Full financialsIn fiscal 2025, IQVIA generated $16.31 billion in revenue, up 5.9% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $1.36 billion (-0.9% year over year), for a net margin of 8.3% versus a median of 7.6% in the prior 5 years. Gross margin was 33.3% (down from 34.9%) and operating margin 13.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B |
| Growth | +5.87% | +2.81% | +3.98% | +3.86% | +22.14% |
| Net income | $1.36B | $1.37B | $1.36B | $1.09B | $966.00M |
| EPS (diluted) | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 |
Analyst forecast
ForecastConsensus (22 analysts)
strong_buy
Avg. price target
$290.84+12.68%
- Strong buy 3
- Buy 16
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $2.95
- Last reported (Q1 2026)
- May 5, 2026
- EPS actual vs est.
- $1.61 vs —
IQV news
All IQV news- Extensive Database & Solid Bookings Benefit IQVIA Amid Low LiquidityNasdaqIQV, PAYX, FISV
- IQVIA Holdings Now #239 Largest Company, Surpassing Vivmark ResidentialNasdaqIQV, VMRK
- IQVIA Stock Rises 60% in 6 Months: Here's What You Should KnowNasdaqIQV, CNC, BTSG
- Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-TermNasdaq
- Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?NasdaqNPCE, IQV
- IQVIA prices $2B of senior notes due 2034Seeking Alpha
- VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate FastNasdaqVEEV, CRM, IQV
- Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?NasdaqTMDX, IQV
IQVIA peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INCYIncyte Corp. | 113.44 | +0.63% | $22.99B | vs IQV |
| MEDPMedpace Holdings Inc. | 604.25 | +0.22% | $16.87B | vs IQV |
| CRLCharles River Laboratories International Inc. | 300.30 | -1.53% | $14.46B | vs IQV |
| ICLRICON plc | 164.08 | +1.48% | $12.66B | vs IQV |
| ABSIAbsci Corporation | 9.22 | -10.22% | $1.58B | vs IQV |
| MXCTMaxCyte Inc. | 1.04 | -4.59% | $107.33M | vs IQV |
| ONMDOneMedNet Corp Class A | 4.91 | -1.21% | $28.60M | vs IQV |
| BIAFbioAffinity Technologies Inc. | 6.16 | +1.65% | $7.19M | vs IQV |
Indexes, lists and sector
Index membership
IQVIA stock FAQ
What is IQVIA's stock price today?
IQV last traded at $258.11 as of Oct 7, 4:03 PM EDT, down 0.72% on the day. Prices are delayed at least 15 minutes.
When is IQVIA's next earnings date?
IQVIA is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $2.95.
What is IQV's P/E ratio?
IQV trades at a trailing P/E ratio of 32.30 and a forward P/E of 17.87, compared with a median of 35.5 for its closest peers.
Is IQVIA in the S&P 500?
Yes. IQVIA (IQV) is a constituent of the S&P 500 index.
Who is IQVIA's CEO?
Mr. Ari Bousbib is the chief executive officer of IQVIA Holdings Inc., which has about 94,000 employees.
What is the IQV 52-week high?
The 52-week high for IQV is $277.40 and the 52-week low is $154.50. The stock is currently 7.0% below its high.